TSP A74

Drug Profile

TSP A74

Alternative Names: TSP-A74

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Perseus Proteomics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD71 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Dec 2016 Preclinical trials in Cancer in Japan (Parenteral) before December 2016
  • 03 Dec 2016 Pharmacodynamics data from a preclinical study in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top